Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2011

View Archived Issues

Results made available from MENZA trial of enzastaurin

First-in-patient study assesses EMD-525797 in metastatic CRPC

Antifibrinolytic MDCO-2010 safe in first-in-patient trial

Roche to expand HCV portfolio with acquisition of Anadys

Anadys reports interim data from setrobuvir study

Controlled-release phentermine/topiramate formulation shows long-term benefit in obesity

Rib-X Pharmaceuticals describes RX-04 program for developing novel antibiotics

Scientists at Roche present novel farnesoid X receptor agonists

New monoamine reuptake inhibitors synthesized by NeuroSearch

Novo Nordisk prepares new glucagon receptor agonists

Krisani Biosciences patents new pain therapeutics

Novel autotaxin inhibitors designed by Merck KGaA

ABI-007 advances through trial in gastric cancer

Ube and Santen form prostanoid EP2 receptor agonist collaboration

ULURU to out-license European rights to Altrazeal

FDA grants accelerated approval to ApoPharma's Ferriprox

VIVUS resubmits NDA for Qnexa

Dendreon begins enrollment in phase II trial of DN24-02

NeoStem acquires Amorcyte and plans phase II stem cell therapy trial

OTSA-101 clear to enter clinic in France

Infinity Pharmaceuticals provides update on IPI-926 trials

Archimedes Pharma launches Lazanda

TONIX Pharmaceuticals completes reverse merger transaction

ChemoCentryx begins phase II CCX-168 trial

AB Science recruits first patient in phase III masitinib trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...